NCT07752407
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 0 → 26 locations
- Notable Recruitment opened
- Eligibility criteria expanded, about 39 words
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants will be administered open-label vonoprazan 10 mg once daily (QD) to be taken orally for 4 weeks during the 4-week run-in period. Participants will be administered vonoprazan 10 mg to be taken orally as needed at the onset of each heartburn episode (maximum of once in a 24-hour period) during the 12-week placebo-controlled timed assessment period and the subsequent 12-week placebo-controlled extension period.
Participants will be administered open-label vonoprazan 10 mg QD to be taken orally for 4 weeks during the 4-week run-in period. Participants will be administered placebo to be taken orally as needed at the onset of each heartburn episode (maximum of once in a 24-hour period) during the 12-week placebo-controlled timed assessment period and the subsequent 12-week placebo-controlled extension period.
Drugs: Vonoprazan, Placebo
Sites
26 sites in 1 country